inclusion criteria: 1. those with full understanding of the clinical study and agreeing with the participation of the clinical study voluntarily in writing, or with a deputy granted with legal authority of the relevant patient if he/she is unable to agree with the clinical study in person 2. adults aged at 19 or above at the time of screening examination (according to the legal age for adult in each country) 3. diagnosis of covid-19 including a positive real time reverse transcription polymerase chain reaction (rt-pcr) for severe acute respiratory syndrome (sars)-cov-2 within 4 days prior to administering the investigational produce (ip) 4. mild or moderate patients who have the following conditions at screening and confirm at randomization at randomization a. mild: those with covid-19 symptoms relevant to the inclusion criteria 5 without breathing difficulty or other chest radiation examination b. moderate: those with disease in respiratory organs in the clinical evaluation or imaging examination (chest radiation examination, etc.) and also relevant to the following conditions * higher than 94% of oxygen saturation (sp02) with room air at screening * lower than 30 times/min respiratory frequency at screening 5. those who happen more than one of the following symptoms within 4 days prior to the treatment of investigational medicinal product (imp) and also have more than one of symptoms within a day prior to the treatment of imp: * fever * cough * shortness of breath * chills * muscle pain * headache * sore throat * loss of smell/taste * nasal congestion * runny nose * fatigue * nausea or vomiting * diarrhea * phlegm 6. those being hospitalized or scheduled in hospital or quarantined facilities or home isolated 7. those comply with the clinical study protocol 8. female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal. effective contraception includes an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms) with spermicide.

inclusion criteria: 1. those with full understanding of the clinical study and agreeing with the participation of the clinical study voluntarily in writing, or with a deputy granted with legal authority of the relevant patient if he/she is unable to agree with the clinical study in person 2. adults aged at 19 or above at the time of screening examination (according to the legal age for adult in each country) 3. diagnosis of covid-19 including a positive real time reverse transcription polymerase chain reaction (rt-pcr) for severe acute respiratory syndrome (sars)-cov-2 within 4 days prior to administering the investigational produce (ip) 4. mild or moderate patients who have the following conditions at screening and confirm at randomization at randomization a. mild: those with covid-19 symptoms relevant to the inclusion criteria 5 without breathing difficulty or other chest radiation examination b. moderate: those with disease in respiratory organs in the clinical evaluation or imaging examination (chest radiation examination, etc.) and also relevant to the following conditions * higher than 94% of oxygen saturation (sp02) with room air at screening * lower than 30 times/min respiratory frequency at screening 5. those who happen more than one of the following symptoms within 4 days prior to the treatment of investigational medicinal product (imp) and also have more than one of symptoms within a day prior to the treatment of imp: * fever * cough * shortness of breath * chills * muscle pain * headache * sore throat * loss of smell/taste * nasal congestion * runny nose * fatigue * nausea or vomiting * diarrhea * phlegm 6. those being hospitalized or scheduled in hospital or quarantined facilities or home isolated 7. those comply with the clinical study protocol 8. female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal. effective contraception includes an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms) with spermicide.

inclusion criteria: those with full understanding of the clinical study and agreeing with the participation of the clinical study voluntarily in writing, or with a deputy granted with legal authority of the relevant patient if he/she is unable to agree with the clinical study in person adults aged at 19 or above at the time of screening examination (according to the legal age for adult in each country) diagnosis of covid-19 including a positive real time reverse transcription polymerase chain reaction (rt-pcr) for severe acute respiratory syndrome (sars)-cov-2 within 4 days prior to administering the investigational produce (ip) mild or moderate patients who have the following conditions at screening and confirm at randomization at randomization a. mild: those with covid-19 symptoms relevant to the inclusion criteria 5 without breathing difficulty or other chest radiation examination b. moderate: those with disease in respiratory organs in the clinical evaluation or imaging examination (chest radiation examination, etc.) and also relevant to the following conditions higher than 94% of oxygen saturation (sp02) with room air at screening lower than 30 times/min respiratory frequency at screening those who happen more than one of the following symptoms within 4 days prior to the treatment of investigational medicinal product (imp) and also have more than one of symptoms within a day prior to the treatment of imp: fever cough shortness of breath chills muscle pain headache sore throat loss of smell/taste nasal congestion runny nose fatigue nausea or vomiting diarrhea phlegm those being hospitalized or scheduled in hospital or quarantined facilities or home isolated those comply with the clinical study protocol female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal. effective contraception includes an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms) with spermicide.

inclusion criteria: those with full understanding of the clinical study and agreeing with the participation of the clinical study voluntarily in writing, or with a deputy granted with legal authority of the relevant patient if he/she is unable to agree with the clinical study in person adults aged at 19 or above at the time of screening examination (according to the legal age for adult in each country) diagnosis of covid-19 including a positive real time reverse transcription polymerase chain reaction (rt-pcr) for severe acute respiratory syndrome (sars)-cov-2 within 4 days prior to administering the investigational produce (ip) mild or moderate patients who have the following conditions at screening and confirm at randomization at randomization a. mild: those with covid-19 symptoms relevant to the inclusion criteria 5 without breathing difficulty or other chest radiation examination b. moderate: those with disease in respiratory organs in the clinical evaluation or imaging examination (chest radiation examination, etc.) and also relevant to the following conditions higher than 94% of oxygen saturation (sp02) with room air at screening lower than 30 times/min respiratory frequency at screening those who happen more than one of the following symptoms within 4 days prior to the treatment of investigational medicinal product (imp) and also have more than one of symptoms within a day prior to the treatment of imp: fever cough shortness of breath chills muscle pain headache sore throat loss of smell/taste nasal congestion runny nose fatigue nausea or vomiting diarrhea phlegm those being hospitalized or scheduled in hospital or quarantined facilities or home isolated those comply with the clinical study protocol female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal. effective contraception includes an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms) with spermicide.